Literature DB >> 29033257

Chromogranin A is not a biomarker of mastocytosis.

Pahul Hanjra1, Chyi-Chia R Lee2, Irina Maric3, Melody Carter1, Ana Olivera1, Dean D Metcalfe1, Hirsh D Komarow4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29033257      PMCID： PMC5845814          DOI： 10.1016/j.jaip.2017.08.022

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


× No keyword cloud information.
  10 in total

1.  Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.

Authors:  Peter Valent; Cem Akin; Michel Arock; Knut Brockow; Joseph H Butterfield; Melody C Carter; Mariana Castells; Luis Escribano; Karin Hartmann; Philip Lieberman; Boguslaw Nedoszytko; Alberto Orfao; Lawrence B Schwartz; Karl Sotlar; Wolfgang R Sperr; Massimo Triggiani; Rudolf Valenta; Hans-Peter Horny; Dean D Metcalfe
Journal:  Int Arch Allergy Immunol       Date:  2011-10-27       Impact factor: 2.749

Review 2.  Chromogranin A: its role in endocrine function and as an endocrine and neuroendocrine tumor marker.

Authors:  L J Deftos
Journal:  Endocr Rev       Date:  1991-05       Impact factor: 19.871

3.  Reference intervals for the Kryptor second-generation chromogranin A assay.

Authors:  Simona Ferraro; Simona Borille; Mauro Panteghini
Journal:  Clin Chem Lab Med       Date:  2016-11-01       Impact factor: 3.694

4.  Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.

Authors:  S Sanduleanu; M Stridsberg; D Jonkers; W Hameeteman; I Biemond; G Lundqvist; C Lamers; R W Stockbrügger
Journal:  Aliment Pharmacol Ther       Date:  1999-02       Impact factor: 8.171

Review 5.  Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.

Authors:  Peter Valent; Cem Akin; Dean D Metcalfe
Journal:  Blood       Date:  2016-12-28       Impact factor: 22.113

6.  Esomeprazole-induced hyperchromograninemia in the absence of concomitant hypergastrinemia.

Authors:  Giovanni Gori; Giacomo Spinelli; Claudio Spinelli; Marco Tuccori; Corrado Blandizzi; Mario Del Tacca
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-10-12       Impact factor: 46.802

7.  Lymphoid cells and tissue mast cells of bone marrow lesions in systemic mastocytosis: a histological and immunohistological study.

Authors:  H P Horny; E Kaiserling
Journal:  Br J Haematol       Date:  1988-08       Impact factor: 6.998

Review 8.  Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options.

Authors:  Gerhard J Molderings; Stefan Brettner; Jürgen Homann; Lawrence B Afrin
Journal:  J Hematol Oncol       Date:  2011-03-22       Impact factor: 17.388

9.  Discontinuation of proton pump inhibitors during assessment of chromogranin A levels in patients with neuroendocrine tumours.

Authors:  C M Korse; M Muller; B G Taal
Journal:  Br J Cancer       Date:  2011-10-11       Impact factor: 7.640

10.  Determination of plasma heparin level improves identification of systemic mast cell activation disease.

Authors:  Milda Vysniauskaite; Hans-Jörg Hertfelder; Johannes Oldenburg; Peter Dreßen; Stefan Brettner; Jürgen Homann; Gerhard J Molderings
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240
  10 in total
  2 in total

Review 1.  Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?

Authors:  Theoharis C Theoharides; Irene Tsilioni; Huali Ren
Journal:  Expert Rev Clin Immunol       Date:  2019-04-22       Impact factor: 4.473

2.  Proceedings from the Inaugural American Initiative in Mast Cell Diseases (AIM) Investigator Conference.

Authors:  Jason Gotlib; Tracy I George; Melody C Carter; K Frank Austen; Bruce Bochner; Daniel F Dwyer; Jonathan J Lyons; Matthew J Hamilton; Joseph Butterfield; Patrizia Bonadonna; Catherine Weiler; Stephen J Galli; Lawrence B Schwartz; Hanneke Oude Elberink; Anne Maitland; Theoharis Theoharides; Celalettin Ustun; Hans-Peter Horny; Alberto Orfao; Michael Deininger; Deepti Radia; Mohamad Jawhar; Hanneke Kluin-Nelemans; Dean D Metcalfe; Michel Arock; Wolfgang R Sperr; Peter Valent; Mariana Castells; Cem Akin
Journal:  J Allergy Clin Immunol       Date:  2021-03-11       Impact factor: 14.290
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.